Welcome to our webcast, “Management of HBV HBeAg (-) Patients", the first in a series of topic specific presentations. The changes in our knowledge of chronic hepatitis B during the past two decades have been profound. The natural history has been more clearly defined, the meaning of serum markers has been redefined with the advents of molecular tests that accurately measure virus directly, and five effective treatments are now available. As a result, patients can benefit greatly, so it is important these advances are rapidly incorporated into clinical practice. I sincerely hope this program provides information to assist you in the management of hepatitis B patients in your own practice. Thank you for participating.

Sincerely,
Eugene R. Schiff, MD MACP, FRCP, MACG

Target Audience

This activity has been designed to meet the educational needs of hepatologists, gastroenterologists and physician assistants involved in the management of chronic hepatitis B.

Goal Statement

To provide important clinical data on the management of HBV

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Discuss management approaches for HBV HBeAg (-) patients
  
  

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the sponsorship of Purdue University, an equal opportunity, equal access institution. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Purdue University designates this educational activity for a maximum of .5 AMA PRA Category 1 Credit (s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release - December 31, 2007

Expiration - December 31, 2008

Faculty Disclosures

Dr. Eddie Cheung has participated on the following speakers' bureau: Roche Pharmaceuticals, Schering Plough, Valeant Pharmaceuticals, Novartis, and Bristol-Myers Squibb.

Program Support

This program is supported by an education grant from Bristol-Myers Squibb and Gilead Pharmaceuticals

Launch Program